A new test to help select colorectal cancer therapy is the first in a menu of rapid cartridge-based tests the firm is planning to support cancer testing.

The companies will use Abbott's RT-PCR Simpli-Collect STI Test for detection and differentiation of the causes of sexually transmitted infections.

The test is a bead-based multiplexed immunoassay that also utilizes a machine learning classifier to determine whether a patient has Lyme disease.

The test uses autofluorescent single-walled carbon nanotubes to detect bacterial cell death in antimicrobial-containing microfluidic channels.

The company recently published a study showing that elemental patterns in single strands of hair are different in patients ...

Stakeholders noted that challenges like supply chain breakdowns and staffing shortages are too global in scope for any one ...

The US District Court for the District of Delaware announced the settlement this week, ending the dispute, which originated as a patent infringement suit by Invitae against Natera.

The grant will support the development of an automated, cartridge-based desktop testing instrument for direct-from-blood detection of yeast infections.

NEW YORK – Digital pathology firm OptraScan plans to launch early next year a service that will provide slide scanners and related software to labs at no charge in exchange for payments per slide for ...

The private equity firms invested along with executive Cary Breese, who is slated to become CEO of the clinical lab.

The agency said that during emergencies it will balance the risks of delaying access to tests compared with the risks of harm from inaccurate test results.